EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry

Edelgard Lindhoff-Last, Inka Wiegratz, Olivia Ott, Yvonne Weil, Christoph Sucker, Susan Halimeh, Holger Seidel iD, Christian Schambeck, Konstantin Kirchmayr, Eva Herrmann

Thrombosis and Haemostasis · 01.09.2026 · 126 (09) · 974-982

DOI: 10.1055/a-2724-4458 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.09.2026. Verfasst von Edelgard Lindhoff-Last und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardioangiology Center Bethanienhospital (CCB), Department of Coagulation Disorders, Frankfurt, Germany. Hauptthemen laut MEDLINE: Menorrhagia, Anticoagulants, Venous Thromboembolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International ERISTA-Grant by the Bristol Myers Squibb, Pfizer Alliance.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heavy menstrual bleeding (HMB) is a common complication of anticoagulant therapy in menstruating women with venous thromboembolism (VTE). Direct oral anticoagulants (DOAC) used for VTE treatment may differ in their menstrual bleeding profiles. Therefore, the prospective multicenter noninterventional investigator-initiated HEMBLED registry (heavy menstrual bleeding in patients treated with DOAC) was performed to analyze spontaneous menstrual bleeding in women treated with therapeutic DOAC doses. A modified pictorial blood assessment chart (PBAC) score was used to define the severity of menstrual bleeding. Patients were only included when they did not use hormonal or intrauterine contraception methods. The prospective follow-up was 4 months. The primary endpoint was the comparison of the PBAC scores between the individual DOAC groups. Overall, 73 patients with 213 monthly assessments of the PBAC scores were analyzed. Patients were on average 35 years old and were anticoagulated with apixaban (62%), rivaroxaban (26%), edoxaban (7%), or dabigatran (6%). The PBAC scores of the rivaroxaban group (mean: 145 points) were significantly increased by 54% compared with the apixaban group (mean: 93 points, p = 0.0193). HMB (PBAC score > 100 points) at least once was detected in 53% of the apixaban group compared with 79% of the rivaroxaban group (p = 0.0913). The duration of menstrual bleeding was numerically shorter in the apixaban group compared with the rivaroxaban group (p = 0.1894). DOAC differ in their influence on the intensity of spontaneous menstrual bleeding. This should be taken into account when advising young women with VTE who need an oral anticoagulant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MenorrhagiaAnticoagulantsVenous ThromboembolismHumansFemaleRegistriesAdultProspective StudiesAdministration, OralMiddle AgedRivaroxabanPyridonesPyrazolesPyridinesDabigatranTreatment OutcomeYoung AdultThiazoles

Substanzen

AnticoagulantsRivaroxabanPyridonesPyrazolesapixabanPyridinesDabigatranedoxabanThiazoles

Autor:innen und Institutionen

  • Cardioangiology Center Bethanienhospital (CCB), Department of Coagulation Disorders, Frankfurt, Germany.
  • Fertility Center Am Palmgarten, Department of Obstetrics and Gynecology, Frankfurt, Germany.
  • Praxisklinik in Mittelhessen, Department of Angiology, Wetzlar, Hessen, Germany.
  • Coagumed Gerinnungszentrum, Department of Haemostaseology, Berlin, Germany.
  • Coagulation Center Rhein-Ruhr, Department of Haemostaseology, Duisburg, Germany.
  • Center for Blood Coagulation Disorders and Transfusion (CBT), Department of Haemostaseology, Bonn and Dortmund, Germany.

ORCID-Profile: Holger Seidel

Förderung

  • International ERISTA-Grant by the Bristol Myers Squibb, Pfizer Alliance

Zitieren

APA

Lindhoff-Last, E., Wiegratz, I., Ott, O., Weil, Y., Sucker, C., Halimeh, S., Seidel, H., Schambeck, C., Kirchmayr, K., & Herrmann, E. (2026). Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry. Thrombosis and Haemostasis, 126(09), 974-982. https://doi.org/10.1055/a-2724-4458

Vancouver

Lindhoff-Last E, Wiegratz I, Ott O, Weil Y, Sucker C, Halimeh S, et al. Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry. Thrombosis and Haemostasis. 2026;126(09):974-982. doi:10.1055/a-2724-4458

BibTeX
@article{LindhoffLast2026,
  author = {Lindhoff-Last, Edelgard and Wiegratz, Inka and Ott, Olivia and Weil, Yvonne and Sucker, Christoph and Halimeh, Susan and Seidel, Holger and Schambeck, Christian and Kirchmayr, Konstantin and Herrmann, Eva},
  title = {Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {09},
  pages = {974--982},
  doi = {10.1055/a-2724-4458}
}
Kostenlos starten →